A Phase 4 interventional study of SSRI and rTMS in Depression, Major Depressive Disorder and Bipolar Depression, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Shanghai Mental Health Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Depression by Shanghai Mental Health Center — 3 open to participants now, 5 under way, none of them phase 3. Depression · Shanghai Mental Health Center.
Among the 15 studies in Depression by Shanghai Mental Health Center, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 4, and was the 12th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →3 of the 15 studies in Depression by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 16–65 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 7–17
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 12 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 120 across the 11 interventional studies, 5,100 across the 4 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
2 of the studies in Depression by Shanghai Mental Health Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05095662Shanghai Mental Health CenterEstablish a Specific Cohort Database for Depressive Disorders | 2026-12-31 |
| NCT06417437Shanghai Mental Health CenterNon-invasive BCI and Application Verification for Depressed People | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Depression by Shanghai Mental Health Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is estimated that more than 350 million people worldwide suffer from depression, with a prevalence rate of 2.1% in China, which is approximately 30 million people.
At present, due to the lack of neurobiological markers for screening and diagnosing depression, the identification and diagnosis of MDD are based on the judgment of professional doctors, and the treatment mostly relies on clinical symptoms.
In terms of treatment, medication remains the main stream for MDD. Although current methods have certain therapeutic effects, patients still suffer from various side effects and poor cognitive function.In current clinical practice, relying purely on symptomatic diagnosis and treatment is difficult to meet the needs of clinical practice, so there is an urgent need to search for neurobiological markers in depression and develop targeted non-invasive intervention technologies.
This study aims to combine advanced brain imaging technology, digital twin-brain models, multi-source information decoding technology, integrated detection and intervention technology. The target is to create two new types of non-invasive BCI systems that can regulate emotions. One is a intervention BCI system for MDD that is suitable for hospital settings with the purpose of precise physical stimulation, and the other one is an ecological BCI system that regulate emotions and intervene with depression which is suitable for both hospital settings and future family environments.
This study will collect a comprehensive collection of physiological and biochemical indicators from patients with depression and from healthy control groups, as well as multimodal information such as head surface electroencephalography, MRI, and eye movements under different brain states, to personalize the available BCI information of depression related brain regions, circuits, and networks. The study also tries to explore emotional-interactive games that can intervene with depression and build a game data base that is dedicated to MDD. Other goals include designing and establishing two new types of emotional regulation systems, which are precise external physical stimulation intervention and ecological intervention, constructing a BCI regulation system, and conducting application verification to evaluate the regulation effect.
This study aims to establish a BCI regulation scheme and system for individuals with mdd, and to conduct validation for this application. Four more detailed contents are being designed, including 1. providing biological markers in brain regions, circuits, and networks that are probably related to MDD, 2. assessment models of the state of brain and multivariate signal mapping models, 3. virtual regulation paradigms, evaluations on the effect of the regulation , and 4. multimodal information collection and regulation software and hardware technologies.
Shanghai Mental Health Center, as the sponsor institution, tends to recruit MDD patients from daily outpatient service. The paticipants' personal information will be noted and then the patients will undergo different assessment on their level of depression, anxiety, anhedonia, manic state, cognitive status, effect and side effects of the current treatment, and their biological rhythm, sleep, quality of life, etc. Peripheral blood will be drawn for different potential biomarkers, as well as multimodal information such as EEG, eye movement, magnetic resonance imaging, magnetoencephalogram, fNIRS, and etc. Then compare the following laboratory indicators between depressed patients and healthy individuals such as differences in the concentration and gene expression of peripheral blood inflammatory factors, oxidative stress indicators, brain-derived neurotrophic factors, brain imaging, electrophysiology, blood oxygen and etc. The work above is to obtain specific neurobiological markers of MDD.
Intervention measures are as follows:
Other technologies used in this study includes:
MDD patients will be divided into different treatment gourds based on theirs condition and whether the chosen treatment would be the most suitable for them. All individuals will undergo the above assessments to establish a comprehensive, multimodal information data base, and finally after comparing the outcome before and after the treatment, the study tries to find out new and effective measures and validate their feasibility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with anhedonia will be using either Bupropion or Voxetine. Patients without anhedonia will be given SSRIs. Frequency and dosage will be guided by psychiatrist. Treatment will last 4 weeks.
Drug: SSRI
In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has decided to be dlpfc. Treatment will last 4 weeks.
Drug: SSRI · Device: rTMS
In addition to medication using SSRIs, patients will be also treated with rTMS. The stimulated brain region has not been decided, but rbitofrontal cortex, cerebellum and others are considered. Treatment will last 4 weeks.
Drug: SSRI · Device: rTMS
In addition to medication using SSRIs, patients will be also treated with Neuro-Training. The process will be guided under fNIRS and monitored by EGG. Treatment will last 4 weeks.
Drug: SSRI · Behavioral: Neuro-Feedback
In addition to medication using SSRIs, patients will be also treated with games that can regulate emotions. Details are not yet decided. Treatment will last 4 weeks.
Drug: SSRI · Behavioral: Game Regulation
Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
Patients will be treated targeting either the traditional brain region or new region.
Patients under 18 years old will first be considered this treatment before other methods.
Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
EEG power in alpha band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks.
Time frame: 2 weeks
EEG power in beta band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 2 weeks.
Time frame: 2 weeks
MRI imaging of DLPFC between the depression patient group and healthy controls.
Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 2 weeks.
Time frame: 2 weeks
HbO in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks.
Time frame: 2 weeks
Hb in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 2 weeks.
Time frame: 2 weeks
EEG power in alpha band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks.
Time frame: 4 weeks
EEG power in beta band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 4 weeks.
Time frame: 4 weeks
MRI imaging of DLPFC between the depression patient group and healthy controls.
Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 4 weeks.
Time frame: 4 weeks
HbO in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks.
Time frame: 4 weeks
Hb in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 4 weeks.
Time frame: 4 weeks
EEG power in alpha band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks.
Time frame: 8 weeks
EEG power in beta band between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by EEG at 8 weeks.
Time frame: 8 weeks
MRI imaging of DLPFC between the depression patient group and healthy controls.
Changes in brain imaging from baseline in multimodal emotional data as assessed by MRI at 8 weeks.
Time frame: 8 weeks
HbO in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks.
Time frame: 8 weeks
Hb in fNIRS between the depression patient group and healthy controls.
Changes from baseline in multimodal emotional data as assessed by fNIRS at 8 weeks.
Time frame: 8 weeks
The score of HAMD-17 in depression patient group and healthy controls.
Changes from baseline in the score of HAMD-17 at 2 weeks
Time frame: 2 weeks
The score of HAMD-17 in depression patient group and healthy controls.
Changes from baseline in depression patient group in the score of HAMD-17 at 4 weeks
Time frame: 4 weeks
The score of HAMD-17 in depression patient group and healthy controls.
Changes from baseline in depression patient group in the score of HAMD-17 at 8 weeks
Time frame: 8 weeks
The change in the state of depression in depression patient groups
The state of depression in patient group measured by SDS(0-80) at 2 weeks.
Time frame: 2 weeks
The change in the state of agitation in depression patient groups
The state of depression in patient group measured by HCL-32(0-32) at 2 weeks.
Time frame: 2 weeks
The change in the state of depression in depression patient groups
The state of depression in patient group measured by SDS(0-80) at 4 weeks.
Time frame: 4 weeks
The change in the state of agitation in depression patient groups
The state of depression in patient group measured by HCL-32(0-32) at 4 weeks.
Time frame: 4 weeks
The change in the state of depression in depression patient groups
The state of depression in patient group measured by SDS(0-80) at 8 weeks.
Time frame: 8 weeks
The change in the state of agitation in depression patient groups
The state of depression in patient group measured by HCL-32(0-32) at 8 weeks.
Time frame: 8 weeks
The change in the state of anhedonia in depression patient groups
The state of depression in patient group measured by SHAPS(0-64) at 2 weeks.
Time frame: 2 weeks
The change in the state of anhedonia in depression patient groups
The state of depression in patient group measured by SHAPS(0-64) at 4 weeks.
Time frame: 4 weeks
The change in the state of anhedonia in depression patient groups
The state of depression in patient group measured by SHAPS(0-64) at 8 weeks.
Time frame: 8 weeks
The change in the state of anxiety in depression patient groups
The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 2 weeks.
Time frame: 2 weeks
The change in the state of anxiety in depression patient groups
The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 4 weeks.
Time frame: 4 weeks
The change in the state of anxiety in depression patient groups
The state of anxiety in patient group measured by different scales including GAD-7(0-56) at 8 weeks.
Time frame: 8 weeks
The change in the level of cognitive function in depression patient group
The level of cognitive function in patient group measured by RBANS at 2 weeks.
Time frame: 2 weeks
The change in the level of cognitive function in depression patient group
The level of cognitive function in patient group measured by RBANS at 4 weeks.
Time frame: 4 weeks
The change in the level of cognitive function in depression patient group
The level of cognitive function in patient group measured by RBANS at 8 weeks.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2027, 48 months after the start.
Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →